The initiation of early ADME screening dramatically decreases the proportion of compounds failing in clinical trials. Our preclinical ADME screening services help customers eliminate weak drug candidates prior to clinical development, thereby helping them to focus their resources on potential drug candidates so that the right drugs get to the right patients faster and more efficiently.

Read our fact sheet to learn how Q² Solutions’ high-throughput ADME screening services can accelerate your preclinical studies.